IDEAYA Biosciences, Inc. Other Research and Development Expense
IDEAYA Biosciences, Inc. (IDYA) reported Other Research and Development Expense of $32.04 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OtherResearchAndDevelopmentExpense · last filed 2026-08-04
- IDEAYA Biosciences, Inc. other research and development expense for the quarter ending 2026-06-30 was $32.04M, a 20.57% increase year-over-year.
- IDEAYA Biosciences, Inc. other research and development expense for the quarter ending 2026-03-31 was $30.39M, a 27.17% increase year-over-year.
- IDEAYA Biosciences, Inc. other research and development expense for the quarter ending 2025-12-31 was $29.69M, a 151.54% increase year-over-year.
- IDEAYA Biosciences, Inc. other research and development expense for the quarter ending 2025-09-30 was $33.43M, a 51.35% increase year-over-year.
- IDEAYA Biosciences, Inc. other research and development expense for fiscal 2025 was $115.72M, a 38.72% increase from fiscal 2024.
- IDEAYA Biosciences, Inc. other research and development expense for fiscal 2024 was $83.42M, a 82.78% increase from fiscal 2023.
- IDEAYA Biosciences, Inc. other research and development expense for fiscal 2023 was $45.64M, a 22.66% increase from fiscal 2022.
- IDEAYA Biosciences, Inc. other research and development expense for fiscal 2022 was $37.21M.
| Period end | Other Research and Development Expense 3 month | Other Research and Development Expense 3 month as first filed | Other Research and Development Expense 6 month | Other Research and Development Expense 6 month as first filed | Other Research and Development Expense 9 month | Other Research and Development Expense 12 month | Other Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $32.04M 10-Q · filed 2026-08-04 | $62.44M 10-Q · filed 2026-08-04 | $92.13M derived: sum of 3 quarters · filed 2026-08-04 | $125.56M derived: sum of 4 quarters · filed 2026-08-04 | |||
| 2026-03-31 | $30.39M 10-Q · filed 2026-08-04 | $60.08M derived: sum of 2 quarters · filed 2026-08-04 | $93.52M derived: sum of 3 quarters · filed 2026-08-04 | $120.09M derived: sum of 4 quarters · filed 2026-08-04 | |||
| 2025-12-31 | $29.69M 10-Q · filed 2026-05-05 | $63.12M derived: sum of 2 quarters · filed 2026-05-05 | $89.70M derived: sum of 3 quarters · filed 2026-05-05 | $115.72M 10-K · filed 2026-02-17 | |||
| 2025-09-30 | $33.43M 10-Q · filed 2025-11-04 | $60.01M derived: sum of 2 quarters · filed 2025-11-04 | $85.87M 10-Q · filed 2025-11-04 | $95.71M derived: sum of 4 quarters · filed 2026-05-05 | |||
| 2025-06-30 | $26.58M 10-Q · filed 2025-08-05 | $48.38M 10-Q · filed 2026-08-04 | $52.44M 10-Q · filed 2025-08-05 | $62.28M derived: sum of 3 quarters · filed 2026-05-05 | $84.37M derived: sum of 4 quarters · filed 2026-05-05 | ||
| 2025-03-31 | $23.90M 10-Q · filed 2026-05-05 | $25.86M 10-Q · filed 2025-05-06 | $35.70M derived: sum of 2 quarters · filed 2026-05-05 | $57.79M derived: sum of 3 quarters · filed 2026-05-05 | $76.77M derived: sum of 4 quarters · filed 2026-05-05 | ||
| 2024-12-31 | $11.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $33.89M derived: sum of 2 quarters · filed 2026-02-17 | $52.87M derived: sum of 3 quarters · filed 2026-02-17 | $83.42M 10-K · filed 2026-02-17 | $158.42M 10-K · filed 2025-02-18 | ||
| 2024-09-30 | $22.09M 10-Q · filed 2025-11-04 | $41.07M derived: sum of 2 quarters · filed 2025-11-04 | $71.62M 10-Q · filed 2025-11-04 | ||||
| 2024-06-30 | $18.98M 10-Q · filed 2025-08-05 | $33.04M 10-Q · filed 2025-08-05 | |||||
| 2024-03-31 | $14.06M 10-Q · filed 2025-05-06 | ||||||
| 2023-12-31 | $45.64M 10-K · filed 2026-02-17 | ||||||
| 2022-12-31 | $37.21M 10-K · filed 2025-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |